## In the Claims

This listing of claims will replace all prior versions and listings of claims in the patent application.

## 1–3. (Canceled)

4. (Currently Amended) A compound of formula I<sub>C1</sub>

$$R_{2}$$
 $R_{3}$ 
 $R_{4}$ 
 $R_{4}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{6}$ 

wherein

A represents hydrogen, alkyl, halogen or cyano;

B represents hydrogen, alkyl or halogen;

 $R^1, R^2$ ,  $R^3$  and  $R^4$  independently represent hydrogen, alkyl, halogen, nitro, cyano or formyl; and  $R^5$  and  $R^6$  independently represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heteroaryl, heteroaryl-alkyl, alkenyl, carboxyalkyl, cyanoalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or  $R^5$  and  $R^6$ , together with the nitrogen atom to which they are attached, form a heterocyclic ring system;

or a salt of the compound of formula I<sub>C1</sub>;

with the proviso that the compound is not:

- {3-[(E)-2-cyano-2-(4-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-m-tolylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-(3-bromo-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-benzylcarbamoyl-2-cyano-vinyl)-indol-1-yl]-acetic acid;

- [3-((E)-2-cyano-2-o-tolylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-p-tolylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-(4-bromo-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-isopropylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-2-(3-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-[[2-(1H-indol-3-yl)ethyl]amino]-3-oxo-1-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-chloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(4-methyl-piperidin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-chloro-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-phenyl-propylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,3-dichloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(5-chloro-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-benzylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid; or and
- {3-[(E)-2-cyano-3-oxo-3-(4-phenyl-piperazin-1-yl)-propenyl]-indol-1-yl}-acetic acid.
- 5. (Canceled)
- 6. (Currently Amended) The compound according to claim 4, wherein the groups R<sup>5</sup> and R<sup>6</sup> do not form a heterocyclic ring system together with the nitrogen atom to which they are attached; or a salt of the compound.
- 7. (Currently Amended) The compound according to claim 6, wherein R<sup>5</sup> is aryl and R<sup>6</sup> is alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroaryl- alkyl, aryl-alkyl or aryl; or a salt of the compound.
- 8. (Currently Amended) The compound according to claim 6, wherein R<sup>5</sup> is aryl-alkyl and R<sup>6</sup> is alkyl, aryl or aryl-alkyl; or a salt of the compound.
- 9. (Currently Amended) The compound according to claim 4, wherein the groups R<sup>5</sup> and R<sup>6</sup> form a heterocyclic ring system together with the nitrogen atom to which they are attached; or a salt of the compound.
- 10. (Currently Amended) The compound according to claim 4, wherein the compound is:
- {3-[(E)-2-cyano-2-(cyclohexylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;

- [3-((E)-2-cyano-2-phenethylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E) 2 cyano 2 isopropylcarbamoyl vinyl) indol-1-yl] acetic acid;
- [3-((E)-2-cyano-2-propylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-cyclohexylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-2-(3-methyl-butylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-cyano-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- [3 [(E) 2 cyano 2 (4 fluoro phenylcarbamoyl) vinyl] indol 1-yl} acetic acid;
- {3-[(E)-2-cyano-2-(4-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(naphthalen-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(biphenyl-4-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- [3-[(E)-2-cyano-2-(352' dimethyl biphenyl 4 ylcarbamoyl) vinyl] indol 1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,2'-dimethyl-biphenyl-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-tert-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(indan-5-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-Sec-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;

- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(4-methoxy-phenyl)-methyl-carbamoyl]-vmyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-p-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[2-(2,4-dichloro-phenoxy)-phenylcarbanioyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-ethyl-9H-carbazol-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3,5-bis-trifluoromethyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(5-methoxy-2-methyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-nitro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-biphenyl-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-methoxy-dibenzofuran-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-1-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-chloro-4-methoxy-phenylcarbamoyl)-2-cyano-vinyl}-indol-1-yl}-acetic acid;
- {3-[(E)-2-(5-chloro-2-methoxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-4-methyl-benzoic acid methyl ester;
- 2-[(E)-3-(l-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- {3-[(E)-2-cyano-2-(4-trifluoromethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-3-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 4-[(E)-3-(l-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid ethyl ester;
- 3-[(E)-3-(l-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- { 3-[(E)-2-cyano-2-(4-trifluoromethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;

- {3-[(E)-2-(4-bromo-3-chloro-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzo[l,3]dioxol-5-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-indol- 1-yl} -acetic acid;
- {3-[(E)-2-cyano-3-(11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-diphenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-indol-1-yl]-acetic acid;
- (3-{(E)-2-[(4-chloro-phenyl)-methyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-diphenethylcarbamoyl-vinyl)-indol~l-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-((R)-l-phenyl-ethyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzyl-methyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-[(4-acetyl-phenyl)-methyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-[(4-acetyl-phenyl)-furan-2-ylmethyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzyl-carboxymethyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-{benzyl-[(E)-3-(l-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloyl]-amino}-propionic acid;
- {3-[(E)-2-cyano-3-(2,3-dihydro-indol-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(carboxymethyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2-cyano-ethyl)-phenyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-[(3-chloro-phenyl)-methyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(allyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-o-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(ethyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;

- [5-bromo-3-((E)-2-(cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-methyl-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-nitro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-7-methyl-indol-1-yl]-acetic acid;
- {3-[(E)-3-(2-chloro-phenothiazin-10-yl)-2-cyano-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2,2-diphenyl-ethyl)-phenyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[phenyl-(3-phenyl-propyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- [3-((E)-2-cyano-2-{[2-(4-fluoro-phenyl)-ethyl]-phenyl-carbamoyl}-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(11H-10-oxa-5-aza-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- { 3-[(E)-2-cyano-2-(isopropyl-phenyl-carbamoyl)-vinyl]-indol-1-y1}-acetic acid;
- (3-{(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzhydryl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(2-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4-difluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(ethyl-naphthalen-1-yl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4,6-trifluoro-phenylcarbanioyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,3,4-trifluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-l-yl)-propenyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;

- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-5-fluoro-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- { 3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(2-trifluoromethyl-phenyl)-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-l-yl)-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-6-methyl-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-6-methyl-indol-1-yl}-acetic acid;

- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-6-methyl-indol-1-yl)- acetic acid;

- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- ${3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-7-methyl-indol-1-yl}-acetic acid; or and$
- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-7-methyl-indol-1-yl)-acetic acid; or a salt of the compound.
- 11. (Currently Amended) The compound according to claim 4, wherein the compound is of formula  $I_{C2}$

$$R_1$$
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_4$ 
 $R_5$ 
 $R_6$ 
 $R_6$ 

wherein

A represents hydrogen, alkyl, halogen or cyano;

B represents hydrogen, alkyl or halogen;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen, alkyl, halogen, nitro, cyano or formyl; and R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heteroaryl, heteroaryl-alkyl, alkenyl, carboxyalkyl, cyanoalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring system; provided that at least one of the following conditions must be met:

 $\diamond$  one of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  is different from a hydrogen atom; or

❖ when R<sup>5</sup> and R<sup>6</sup> are such that they do not form a heterocyclic ring system together with the nitrogen atom to which they are attached, then both R<sup>5</sup> and R<sub>6</sub>-R<sup>6</sup> are different from hydrogen and one of R<sup>5</sup> and R<sup>6</sup> is different from alkyl; or

when R<sup>5</sup> and R<sup>6</sup> are such that they form a heterocyclic ring system together with the nitrogen atom to which they are attached, then said heterocyclic ring system is neither an unsubstituted or substituted piperidine nor an unsubstituted or substituted piperazine; or a salt of the compound.

- 12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 4 and a pharmaceutically acceptable carrier.
- 13. (Withdrawn) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim 4.
- 14. (Canceled).
- 15. (Canceled).
- 16. (Canceled)
- 17. (Canceled)
- 18. (Withdrawn) The method for preventing or treating chronic or acute allergic immune disorder of claim 13, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.
- 19. (Previously Presented) The compound of claim 4, wherein the compound is {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid.
- 20. (Currently Amended) The compound of claim 4, wherein:
- A is cyano;
- ❖ B is hydrogen or methyl;
- $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are all hydrogen atoms or one of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  is halogen while the others are all hydrogen; and
- ❖ at least one of R<sup>5</sup> and R<sup>6</sup> is <u>a chosen from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or <del>and</del></u>

aryloxy-aryl; or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring system; or a salt of the compound.

- 21. (Withdrawn) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim 20.
- 22. (Withdrawn) The method for preventing or treating a chronic or acute allergic immune disorder of claim 21, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.
- 23. (Withdrawn) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim 10.
- 24. (Withdrawn) The method for preventing or treating a chronic or acute allergic immune disorder of claim 23, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.